查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1339255

麻风病治疗药物市场,份额,规模,趋势,行业分析报告:按药物类别,疾病类型,给药途径,分销管道,地区,细分市场,预测2023-2032年

Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 112 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究显示，到2032年，全球麻风病药物市场规模预计将达到50.33亿美元。该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

由于皮肤病的盛行率不断增加，对治疗麻风病的药物的需求正在迅速扩大。在中国和印度等国家，牛皮癣和麻风病等皮肤病的盛行率正在增加，这推动了市场的发展。根据世界卫生组织 (WHO) 统计，大约 120 个国家出现麻风病例，每年报告病例超过 20 万例。数亿人受到皮肤 NTD 的影响。

此外，麻风病作为一种被忽视的热带疾病，损害了边缘人群（主要生活在偏远农村地区）的生活水平，造成难以言喻的不适、痛苦、耻辱和心理困扰。由于发病率高，世界上一些地区的发生率和传播率都很高。世界卫生组织估计，在过去 20 年里，大约有 1,600 万名麻风病患者接受了治疗。因此，皮肤病患病率的上升和 NTD 的盛行率增加了对麻风病药物的需求，推动了预测期内的市场成长。

据世界卫生组织称，过去十年需要接受被忽视热带疾病干预的人数减少了 25%，2020 年至 2021 年将减少约 8,000 万人。此外，以残障寿命衡量的疾病负担也持续下降。2016年至2019年，每年有超过10亿人接受治疗。到 2022 年底，47 个国家已消除至少一种被忽视的热带疾病。

然而，新冠肺炎 (COVID-19) 疫情严重影响了 NTD 项目，导致社区干预措施的实施减少、医疗机构提供的服务以及医疗用品供应链的获取受到限制，导致这一良好趋势崩溃。因此，从 2019 年到 2020 年，接受 NTD 治疗的人数减少了 34%。

麻风病治疗药物市场报告亮点

由于氨苯□是治疗痲疯病的第一线药物，注射给药途径部分预计在预测期内将以显着的复合年增长率成长。

预计抗结核药物在预测期内将占很大的市场份额，因为利福平等药物可治疗结核病和痲疯病。

由于患病率上升以及政府支持治疗的计划，预计亚太地区在预测期内将以显着的复合年增长率增长。

目录

第 1 章 简介

第二章执行摘要

第三章研究方法论

第四章 全球麻风病药物市场洞察

  • 痲疯治疗 - 产业概况
  • 麻风病药物市场动态
    • 驱动因素和机遇
      • 技术进步
      • 麻风病药物技术在医疗保健中的使用增加
    • 限制因素和挑战
      • 数位化程度的提高限制了市场成长
  • PESTLE分析
  • 麻风病药物产业的趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第五章 全球麻风病药物市场（依药物类别）

  • 主要发现
  • 介绍
  • 抗菌剂
  • 麻风
  • □
  • 赖氨酸
  • 抗结核药
  • 其他

第六章全球麻风病治疗药物市场（依疾病类型）

  • 主要发现
  • 介绍
  • 储袋细菌性痲疯病
  • 多种微生物麻风病

第七章 全球麻风病药物市场（依给药途径）

  • 主要发现
  • 介绍
  • 口服
  • 注射
  • 当地的

第八章全球汉森疾病治疗药物市场（按分销管道）

  • 主要发现
  • 介绍
  • 医院药房
  • 零售药店
  • 药店
  • 网上药店

第九章全球麻风病治疗药物市场（按地区）

  • 主要发现
  • 介绍
    • 2019-2032 年麻风病治疗药物市场评估（按地区）
  • 麻风病药物市场 - 北美
    • 北美：麻风病药物市场，依药物类别，2019-2032
    • 北美：麻风病治疗药物市场，依通路划分，2019-2032
    • 北美：麻风病药物市场，依疾病类型划分，2019-2032 年
    • 北美：麻风病药物市场，依给药途径划分，2019-2032 年
    • 麻风病治疗药物市场—美国
    • 麻风病药物市场 - 加拿大
  • 麻风病药物市场－欧洲
    • 欧洲：麻风病药物市场，依药物类别，2019-2032 年
    • 欧洲：麻风病药物市场，依通路划分，2019-2032 年
    • 欧洲：麻风病药物市场，依疾病类型划分，2019-2032 年
    • 欧洲：麻风病药物市场，依给药途径，2019-2032
    • 痲疯病药物市场 - 英国
    • 麻风病药品市场—法国
    • 麻风病药品市场—德国
    • 麻风病药品市场－义大利
    • 麻风病药品市场－西班牙
    • 麻风病药物市场－荷兰
    • 麻风病药品市场－俄罗斯
  • 麻风病药物市场 - 亚太地区
    • 亚太地区：2019-2032 年痲疯病药物市场（依药物类别）
    • 亚太地区：痲疯病药物市场，依通路划分，2019-2032 年
    • 亚太地区：痲疯病药物市场，依疾病类型，2019-2032
    • 亚太地区：痲疯病药物市场，依给药途径划分，2019-2032 年
    • 痲疯病药物市场—中国
    • 麻风病药物市场 - 印度
    • 汉森病治疗药物市场—日本
    • 麻风病药物市场 - 马来西亚
    • 麻风病药物市场—印度尼西亚
    • 汉森病治疗药物市场—韩国
  • 痲疯病药物市场—中东和非洲
    • 中东和非洲：2019-2032 年麻风病药物市场（依药物类别）
    • 中东和非洲：2019-2032 年麻风病药物市场（按分销管道）
    • 中东和非洲：2019-2032 年麻风病药物市场（按疾病类型）
    • 中东和非洲：2019-2032 年麻风病药物市场（依给药途径）
    • 麻风病药物市场－沙乌地阿拉伯
    • 痲疯病药物市场－南非
    • 痲疯病药物市场－以色列
    • 痲疯病药物市场－阿拉伯联合大公国
  • 痲疯病药物市场－拉丁美洲
    • 拉丁美洲：2019-2032 年痲疯病药物市场（依药物类别）
    • 拉丁美洲：麻风病药物市场，依通路划分，2019-2032 年
    • 拉丁美洲：2019-2032 年麻风病药物市场（依疾病类型）
    • 拉丁美洲：麻风病药物市场，依给药途径划分，2019-2032 年
    • 麻风病药品市场—墨西哥
    • 麻风病药物市场－巴西
    • 痲疯病药品市场－阿根廷

第10章竞争格局

  • 扩张和收购分析
    • 扩张
    • 获得
  • 伙伴关係/协作/协议/揭露
  • Acme Pharmaceuticals
  • Astra Zeneca
  • Bayer
  • Bristol-Myers
  • Cadila Pharmaceuticals
  • Eli Lily
  • Genetic Pharma
  • GSK
  • IDPL
  • Johnson & Johnson
  • Lark Laboratories
  • Merck
  • Macleods Pharmaceuticals
  • Novartis
  • Pfizer
  • Systopic Laboratories
  • Sanofi
  • Teva Pharmaceutical
Product Code: PM3635

The global Leprosy Treatment market size is expected to reach USD 5,000.33 million by 2032, according to a new study by Polaris Market Research. The report "Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial, Leprostatics, Sulfone, Phenazine, Anti-tubercular Drugs, and Others); By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The demand for leprosy treatment is growing more quickly due to the increasing incidence of skin diseases. The prevalence of skin conditions like psoriasis and leprosy has increased in nations like China and India, which has fueled the market. According to the World Health Organization, around 120 countries have leprosy cases, and more than 200,000 cases are reported yearly. Hundreds of millions of people have skin NTDs.

Additionally, leprosy, an NTD, hurts the standard of living of mainly marginalized populations in remote rural areas and causes immense discomfort, suffering, stigmatization, and mental distress. The prevalence of high occurrences provides that some regions of the world experience both high incidence and high transmission rates. In the past 20 years, the WHO estimates that approximately 16 million leprosy cases have been treated. Therefore, the rising prevalence of skin disease and NTD prevalence has increased the demand for leprosy treatment, driving the market's growth over the forecast period.

As per the WHO, the number of people needing interventions for NTDs has fallen by 25% over the past ten years, by about 80 million people between 2020 and 2021. Additionally, there is a consistent decline in the disease burden measured in years of life with a disability. Between 2016 and 2019, more than one billion individuals received treatment annually. By the end of 2022, 47 nations had eliminated at least one NTD.

However, the COVID-19 pandemic severely affected NTD programs, which resulted in a decrease in the implementation of community-based interventions, a restriction on access to services provided by healthcare facilities, and negative effects on the supply chains for medical supplies, disrupting this promising trend. As a result, between 2019 and 2020, 34% fewer people were treated for NTDs.

Leprosy Treatment Market Report Highlights

The injectable route of administration segment is anticipated to grow at a significant CAGR over the forecast period owing to the drug of first preference for treating leprosy being dapsone.

Anti-tubercular drugs are expected to hold a significant market share over the forecast period due to drugs such as Rifampin treating both TB and leprosy.

Asia-Pacific is expected to grow at a considerable CAGR over the projected period on account of the rising disease prevalence as well as the government programs to support the treatment.

The global players include: Astra Zeneca, Bayer, GSK, Johnson & Johnson, Merck, Pfizer Inc., Systopic Laboratories, Sanofi, and Teva Pharmaceutical.

Polaris Market Research has segmented the Leprosy Treatment market report based on drug class, route of administration, disease type, distribution channel, and region:

Leprosy Treatment, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

  • Antibacterial
  • Leprostatics
  • Sulfone
  • Phenazine
  • Anti-tubercular Drugs
  • Others

Leprosy Treatment, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Injectable
  • Topical

Leprosy Treatment, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Paucibacillary Leprosy
  • Multibacillary Leprosy

Leprosy Treatment, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Leprosy Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Leprosy Treatment Market Insights

  • 4.1. Leprosy Treatment - Industry Snapshot
  • 4.2. Leprosy Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Technological advancement
      • 4.2.1.2. Increasing use of Leprosy Treatment technology in healthcare
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Increasing digitization will restrict the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Leprosy Treatment Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Leprosy Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • 5.3. Antibacterial
    • 5.3.1. Global Leprosy Treatment Market, by Antibacterial, by Region, 2019-2032 (USD Million)
  • 5.4. Leprostatics
    • 5.4.1. Global Leprosy Treatment Market, by Leprostatics, by Region, 2019-2032 (USD Million)
  • 5.5. Sulfone
    • 5.5.1. Global Leprosy Treatment Market, by Sulfone, by Region, 2019-2032 (USD Million)
  • 5.6. Phenazine
    • 5.6.1. Global Leprosy Treatment Market, by Phenazine, by Region, 2019-2032 (USD Million)
  • 5.7. Anti-tubercular Drugs
    • 5.7.1. Global Leprosy Treatment Market, by Anti-tubercular Drugs, by Region, 2019-2032 (USD Million)
  • 5.8. Others
    • 5.8.1. Global Leprosy Treatment Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Leprosy Treatment Market, by Disease Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • 6.3. Paucibacillary Leprosy
    • 6.3.1. Global Leprosy Treatment Market, by Paucibacillary Leprosy, by Region, 2019-2032 (USD Million)
  • 6.4. Multibacillary Leprosy
    • 6.4.1. Global Leprosy Treatment Market, by Multibacillary Leprosy, by Region, 2019-2032 (USD Million)

7. Global Leprosy Treatment Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 7.3. Oral
    • 7.3.1. Global Leprosy Treatment Market, by Oral, by Region, 2019-2032 (USD Million)
  • 7.4. Injectable
    • 7.4.1. Global Leprosy Treatment Market, by Injectable, by Region, 2019-2032 (USD Million)
  • 7.5. Topical
    • 7.5.1. Global Leprosy Treatment Market, by Topical, by Region, 2019-2032 (USD Million)

8. Global Leprosy Treatment Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 8.3. Hospital Pharmacies
    • 8.3.1. Global Leprosy Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
  • 8.4. Retail Pharmacies
    • 8.4.1. Global Leprosy Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
  • 8.5. Drug Stores
    • 8.5.1. Global Leprosy Treatment Market, by Drug Stores, by Region, 2019-2032 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Global Leprosy Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Million)

9. Global Leprosy Treatment Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Leprosy Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • 9.3. Leprosy Treatment Market - North America
    • 9.3.1. North America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.3.2. North America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.3.3. North America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.3.4. North America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.3.5. Leprosy Treatment Market - U.S.
      • 9.3.5.1. U.S.: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.3.5.2. U.S.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.3.5.3. U.S.: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.3.5.4. U.S.: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.3.6. Leprosy Treatment Market - Canada
      • 9.3.6.1. Canada: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.3.6.2. Canada: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.3.6.3. Canada: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.3.6.4. Canada: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.4. Leprosy Treatment Market - Europe
    • 9.4.1. Europe: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.4.2. Europe: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.4.3. Europe: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.4.4. Europe: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.5. Leprosy Treatment Market - UK
      • 9.4.5.1. UK: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.5.2. UK: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.5.3. UK: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.5.4. UK: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.6. Leprosy Treatment Market - France
      • 9.4.6.1. France: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.6.2. France: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.6.3. France: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.6.4. France: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.7. Leprosy Treatment Market - Germany
      • 9.4.7.1. Germany: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.7.2. Germany: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.7.3. Germany: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.7.4. Germany: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.8. Leprosy Treatment Market - Italy
      • 9.4.8.1. Italy: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.8.2. Italy: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.8.3. Italy: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.8.4. Italy: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.9. Leprosy Treatment Market - Spain
      • 9.4.9.1. Spain: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.9.2. Spain: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.9.3. Spain: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.9.4. Spain: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.10. Leprosy Treatment Market - Netherlands
      • 9.4.10.1. Netherlands: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.10.2. Netherlands: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.10.3. Netherlands: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.10.4. Netherlands: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.4.11. Leprosy Treatment Market - Russia
      • 9.4.11.1. Russia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.4.11.2. Russia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.4.11.3. Russia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.4.11.4. Russia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.5. Leprosy Treatment Market - Asia Pacific
    • 9.5.1. Asia Pacific: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.5.2. Asia Pacific: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.5.3. Asia Pacific: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.5.4. Asia Pacific: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.5. Leprosy Treatment Market - China
      • 9.5.5.1. China: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.5.2. China.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.5.3. China: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.5.4. China: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.6. Leprosy Treatment Market - India
      • 9.5.6.1. India: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.6.2. India.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.6.3. India: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.6.4. India: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.7. Leprosy Treatment Market - Japan
      • 9.5.7.1. Japan: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.7.2. Japan.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.7.3. Japan: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.7.4. Japan: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.8. Leprosy Treatment Market - Malaysia
      • 9.5.8.1. Malaysia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.8.2. Malaysia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.8.3. Malaysia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.8.4. Malaysia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.9. Leprosy Treatment Market - Indonesia
      • 9.5.9.1. Indonesia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.9.2. Indonesia.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.9.3. Indonesia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.9.4. Indonesia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.5.10. Leprosy Treatment Market - South Korea
      • 9.5.10.1. South Korea: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.5.10.2. South Korea.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.5.10.3. South Korea: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.5.10.4. South Korea: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.6. Leprosy Treatment Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.6.2. Middle East & Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.6.3. Middle East & Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.6.4. Middle East & Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.5. Leprosy Treatment Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.5.2. Saudi Arabia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.5.3. Saudi Arabia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.5.4. Saudi Arabia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.6. Leprosy Treatment Market - South Africa
      • 9.6.6.1. South Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.6.2. South Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.6.3. South Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.6.4. South Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.7. Leprosy Treatment Market - Israel
      • 9.6.7.1. Israel: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.7.2. Israel: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.7.3. Israel: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.7.4. Israel: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.6.8. Leprosy Treatment Market - UAE
      • 9.6.8.1. UAE: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.6.8.2. UAE: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.6.8.3. UAE: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.6.8.4. UAE: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • 9.7. Leprosy Treatment Market - Latin America
    • 9.7.1. Latin America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
    • 9.7.2. Latin America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 9.7.3. Latin America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
    • 9.7.4. Latin America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.5. Leprosy Treatment Market - Mexico
      • 9.7.5.1. Mexico: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.5.2. Mexico: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.5.3. Mexico: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.5.4. Mexico: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.6. Leprosy Treatment Market - Brazil
      • 9.7.6.1. Brazil: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.6.2. Brazil: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.6.3. Brazil: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.6.4. Brazil: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
    • 9.7.7. Leprosy Treatment Market - Argentina
      • 9.7.7.1. Argentina: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
      • 9.7.7.2. Argentina: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 9.7.7.3. Argentina: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
      • 9.7.7.4. Argentina: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions
  • 11.1. Acme Pharmaceuticals
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Astra Zeneca
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bayer
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Bristol-Myers
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Cadila Pharmaceuticals
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Eli Lily
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Genetic Pharma
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. GSK
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. IDPL
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Johnson & Johnson
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Lark Laboratories
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Merck
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13.Macleods Pharmaceuticals
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Novartis
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Pfizer
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Systopic Laboratories
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Sanofi
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Teva Pharmaceutical
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development

List of Tables

  • Table 1 Global Leprosy Treatment Market, by Drug Class, by Region, 2019-2032 (USD Million)
  • Table 2 Global Leprosy Treatment Market, by Disease Type, by Region, 2019-2032 (USD Million)
  • Table 3 Global Leprosy Treatment Market, by Route of Administration, by Region, 2019-2032 (USD Million)
  • Table 4 Global Leprosy Treatment Market, by Distribution Channel, by Region, 2019-2032 (USD Million)
  • Table 5 Leprosy Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 6 North America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 7 North America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 8 North America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 9 North America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 10 U.S.: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 11 U.S.: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 12 U.S.: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 13 U.S.: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 14 Canada: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 15 Canada: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 16 Canada: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 17 Canada: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 18 Europe: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 19 Europe: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 20 Europe: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 21 Europe: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 22 Germany: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 23 Germany: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 24 Germany: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 25 Germany: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 26 France: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 27 France: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 28 France: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 29 France: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 30 UK: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 31 UK: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 32 UK: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 33 UK: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 34 Italy: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 35 Italy: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 36 Italy: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 37 Italy: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 38 Netherlands: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 39 Netherlands: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 40 Netherlands: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 41 Netherlands: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 42 Spain: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 43 Spain: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 44 Spain: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 45 Spain: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 46 Russia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 47 Russia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 48 Russia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 49 Russia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 50 Asia Pacific: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 51 Asia Pacific: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 52 Asia Pacific: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 53 Asia Pacific: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 54 China: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 55 China: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 56 China: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 57 China: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 58 Japan: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 59 Japan: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 60 Japan: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 61 Japan: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 62 India: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 63 India: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 64 India: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 65 India: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 66 Indonesia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 67 Indonesia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 68 Indonesia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 69 Indonesia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 70 Malaysia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 71 Malaysia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 72 Malaysia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 73 Malaysia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 74 South Korea: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 75 South Korea: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 76 South Korea: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 77 South Korea: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 78 Latin America: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 79 Latin America: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 80 Latin America: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 81 Latin America: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 82 Brazil: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 83 Brazil: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 84 Brazil: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 85 Brazil: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 86 Mexico: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 87 Mexico: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 88 Mexico: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 89 Mexico: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 90 Argentina: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 91 Argentina: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 92 Argentina: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 93 Argentina: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 94 Middle East & Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 95 Middle East & Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 96 Middle East & Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 97 Middle East & Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 98 UAE: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 99 UAE: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 100 UAE: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 101 UAE: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 102 Saudi Arabia: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 103 Saudi Arabia: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 104 Saudi Arabia: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 105 Saudi Arabia: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 106 South Africa: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 107 South Africa: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 108 South Africa: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 109 South Africa: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 110 Israel: Leprosy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • Table 111 Israel: Leprosy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • Table 112 Israel: Leprosy Treatment Market, by Route of Administration, 2019-2032 (USD Million)
  • Table 113 Israel: Leprosy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Leprosy Treatment Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Leprosy Treatment Market, by Drug Class, 2021 & 2030 (USD Million)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Leprosy Treatment Market, by Distribution Channel, 2021 & 2030 (USD Million)
  • Figure 10. Market by Disease Type
  • Figure 11. Global Leprosy Treatment Market, by Disease Type, 2021 & 2030 (USD Million)
  • Figure 12. Market by Route of Administration
  • Figure 13. Global Leprosy Treatment Market, by Route of Administration, 2021 & 2030 (USD Million)